These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32673446)

  • 1. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
    Ogasawara K; Xu C; Yin J; Darpo B; Carayannopoulos L; Xue H; Palmisano M; Krishna G
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):366-375. PubMed ID: 32673446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
    Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
    Iyer GR; Darpo B; Xue H; Lecot J; Zack J; Bebrevska L; Weis W; Jones I; Drollmann A
    Clin Pharmacol Drug Dev; 2024 May; 13(5):572-584. PubMed ID: 38284433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting.
    Fox GM; Albayaty M; Walker JL; Xue H; Darpo B
    Anesth Analg; 2021 Jan; 132(1):150-159. PubMed ID: 31913911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
    Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
    Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.
    Zhang M; Xu C; Ma L; Shamiyeh E; Yin J; von Moltke LL; Smith WB
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):315-21. PubMed ID: 27136912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.
    Dickinson A; Liu Y; Uvarov A; Peyret T; Marier JF; Chin C; Tran JQ
    Clin Transl Sci; 2024 May; 17(5):e13808. PubMed ID: 38700272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
    Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.
    Ogasawara K; Vince B; Xu C; Zhang M; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 May; 85(5):995-1001. PubMed ID: 32318809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
    Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
    Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of enzastaurin and its metabolites on the QT interval in cancer patients.
    Welch PA; Ng WT; Darstein CL; Musib L; Lesimple T
    J Clin Pharmacol; 2016 Jan; 56(1):101-8. PubMed ID: 26096682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors.
    Zhou X; Richardson DL; Dowlati A; Goel S; Sahebjam S; Strauss J; Chawla S; Wang D; Mould DR; Samnotra V; Faller DV; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2023 Mar; 12(3):257-266. PubMed ID: 36382849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and -2 studies.
    Jewell RC; Mills RJ; Farrell C; Visser SAG
    Br J Clin Pharmacol; 2024 Oct; 90(10):2571-2581. PubMed ID: 38924122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.